The historical rank and industry rank for Editas Medicine's Days Payable or its related term are showing as below:
EDIT's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
Editas Medicine's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Editas Medicine Days Payable Related Terms
Editas Medicine Days Payable Historical Data
* Premium members only.
The historical data trend for Editas Medicine's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Editas Medicine's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Days Payable distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Editas Medicine's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (EDIT) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #999999 out of 707 companies in the Biotechnology industry.
Is Editas Medicine's Days Payable too high?
Editas Medicine's current Days Payable is 0.00. Based on the distribution chart, Editas Medicine ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Editas Medicine has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Days Payable compare to PRTA and XOMA?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #999999 out of 707 companies for Days Payable. This places Editas Medicine in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Editas Medicine and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $2.86 — trading 49% above its estimated fair value. The current Days Payable is 0.00. Editas Medicine's overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $2.86 is trading 49% above its estimated GF Value™ of $1.92.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
Days Payable: 0.00
GF Value™: $1.92 vs. price of $2.86 (49% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
54GF Score
Get the complete analysis for EDIT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
